| 2. |
- Yannuzzi, M., et al.
(författare)
-
TEFIS: A Single Access Point for Conducting Multifaceted Experiments on Heterogeneous Test Facilities
- 2014
-
Ingår i: Computer Networks. - : Elsevier BV. - 1389-1286 .- 1872-7069. ; 63, s. 147-172
-
Tidskriftsartikel (refereegranskat)abstract
- A few years ago, an experimental facility composed of networking gear and simulation tools was sufficient for testing the main features of a prototype before the final product could be launched to the Internet market. This paradigm has certainly changed, but the lack of platforms enabling the realistic assessment of the different facets of a product, including cross-cutting trials across different testbeds, poses strong limitations for researchers and developers. In light of this, we present an open platform that offers a versatile combination of heterogeneous experimental facilities called “TEstbed for Future Internet Services” (TEFIS). TEFIS provides a single access point for conducting cutting-edge experiments on testbeds that supply different capabilities, including testbeds dedicated to network performance, software performance, grid computing, and living labs. We shall show that TEFIS covers the entire life-cycle of a multifaceted experiment, with the advantage that a single testrun can seamlessly execute across different experimental facilities. In order to demonstrate the potential and versatility of the TEFIS platform, we describe the deployment of four distinct experiments and provide a set of results highlighting the benefits of using TEFIS. The experiments described in this article cover: i) the experimentation with an open API called OPENER (which is an open and programmable environment for managing experimentation with SDN applications); ii) an application for skiers and tourists at the Megève ski resort in France; iii) an application that can dynamically adapt the Quality of Experience (QoE) of multimedia services for mobile users; and iv) an augmented reality workspace for remote education and learning purposes based on videoconferencing.
|
|
| 4. |
- Andermann, E., et al.
(författare)
-
Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures
- 2018
-
Ingår i: Epilepsy and Behavior. - : Elsevier BV. - 1525-5050. ; 82, s. 119-127
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To evaluate the nature and incidence of psychiatric and cognitive adverse events (AEs) reported with eslicarbazepine acetate (ESL) used as adjunctive treatment for refractory partial-onset seizures (POS) in adults. Methods: This was a post-hoc analysis of data pooled from three randomized double-blind, placebo-controlled trials (BIA-2093-301, -302, -304). After an 8-week baseline period, patients received placebo or adjunctive ESL 400 mg (studies 301 and 302 only), 800 mg, or 1200 mg once daily (QD) for 14 weeks (2-week titration period, 12-week maintenance period). Psychiatric and cognitive AEs were identified from individual patient data. Suicidality was also evaluated using the Columbia-Classification Algorithm of Suicide Assessment (C-CASA), or the Columbia-Suicide Severity Rating Scale (C-SSRS). P-values were obtained using the chi-square test of independence or Fisher's exact test, without correcting for multiplicity. Results: The analysis population included 1447 patients (ESL, n = 1021; placebo, n = 426). Psychiatric treatment-emergent AEs (TEAEs) occurred in 10.8% of patients receiving ESL, and in a comparable proportion (10.3%) of patients receiving placebo (p = 0.802). The incidence of depression and suicidality-related TEAEs was higher for ESL (7.4%) vs. placebo (3.8%) (p = 0.009). The occurrence of these TEAEs differed between treatment groups (p = 0.010), but there was no notable trend between increasing ESL dose and increasing incidence of depression and suicidality-related TEAEs. Aggression/hostility-related TEAEs occurred in <0.1% of patients taking ESL vs. 0.9% taking placebo. The incidence of cognitive TEAEs was higher for ESL (7.1%) vs. placebo (4.0%) (p = 0.023); incidences of memory impairment, attention disturbance, apathy, and aphasia were higher for ESL 1200 mg than for other treatment groups. Incidences of psychiatric and cognitive serious AEs were (0.6% and 0.2% with ESL, and 0.5% and 0% with placebo, respectively. Psychiatric and cognitive TEAEs leading to discontinuation occurred in 1.9% and 1.4% of patients taking ESL. and 0.7% and 0.5% taking placebo, respectively. Conclusions: In phase III clinical trials of adjunctive ESL for treatment-refractory POS, psychiatric and cognitive TEAEs were reported infrequently with ESL and placebo. The incidences of depression and suicidality-related TEAEs and of cognitive TEAEs were higher for patients taking ESL vs. placebo. Incidences of psychiatric and cognitive SAEs, and TEAEs leading to discontinuation, were low with ESL and placebo. © 2017
|
|
